Overview

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

Status:
Completed
Trial end date:
2017-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of the potent CYP3A4 inhibitor itraconazole on the single-dose PK of TAK-954.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Hydroxyitraconazole
Itraconazole